VYNE Therapeutics, Inc. (VYNE)

NASDAQ: VYNE · IEX Real-Time Price · USD
0.332
-0.010 (-3.04%)
At close: Aug 18, 2022 4:00 PM
0.340
+0.008 (2.533%)
After-hours: Aug 18, 2022 6:32 PM EDT
-3.04%
Market Cap 19.23M
Revenue (ttm) 6.68M
Net Income (ttm) -36.66M
Shares Out 58.01M
EPS (ttm) -0.91
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 295,926
Open 0.347
Previous Close 0.342
Day's Range 0.321 - 0.347
52-Week Range 0.256 - 1.750
Beta 0.67
Analysts Buy
Price Target 5.61 (+1,591.8%)
Earnings Date Aug 10, 2022

About VYNE

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammator... [Read more...]

Industry Biotechnology
IPO Date Jan 25, 2018
Employees 28
Stock Exchange NASDAQ
Ticker Symbol VYNE
Full Company Profile

Financial Performance

In 2021, VYNE's revenue was $14.76 million, a decrease of -29.71% compared to the previous year's $20.99 million. Losses were -$73.33 million, -71.31% less than in 2020.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for VYNE stock is "Buy." The 12-month stock price forecast is 5.61, which is an increase of 1,591.80% from the latest price.

Price Target
$5.61
(1,591.80% upside)
Analyst Consensus: Buy
Stock Forecasts

News

All You Need to Know About VYNE Therapeutics Inc. (VYNE) Rating Upgrade to Buy

VYNE Therapeutics Inc. (VYNE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Misses Revenue Estimates

VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 13.33% and 58%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

VYNE Therapeutics Reports Second Quarter 2022 Financial Results

BRIDGEWATER, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated t...

VYNE Therapeutics Announces Results from its Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic De...

BRIDGEWATER, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated t...

VYNE Therapeutics to Present at the B&T Cell-Mediated Autoimmune Disease Drug Development Conference

BRIDGEWATER, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated t...

VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Derma...

Top-line Efficacy Results Expected in Approximately 6 to 8 Weeks Top-line Efficacy Results Expected in Approximately 6 to 8 Weeks

VYNE Therapeutics to Present at HC Wainwright & Co. Global Investment Conference

BRIDGEWATER, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated th...

VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates

VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 6.67% and 67.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

VYNE Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

Announced positive Phase 1b data for FMX114 in mild-to-moderate atopic dermatitis

VYNE Hosting Key Opinion Leader Event on Novel InhiBET™ BET Inhibitor Platform

Webinar on Tuesday, May 17, 2022 at 10:00 a.m. ET Webinar on Tuesday, May 17, 2022 at 10:00 a.m. ET

VYNE Therapeutics to Present at LifeSci Partners' Immunology & Inflammation Symposium on May 10th

BRIDGEWATER, N.J., May 06, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated th...

VYNE Therapeutics Inc. (VYNE) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

VYNE Therapeutics Inc. (VYNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

VYNE Therapeutics Shares Gain After Positive Atopic Dermatitis Trial Of FMX114

VYNE Therapeutics Inc (NASDAQ: VYNE) announced positive efficacy results from the Phase 1b segment of Phase 1b/2a trial of FMX114 in mild-to-moderate atopic dermatitis (AD). Mean Atopic Dermatitis Sever...

VYNE Therapeutics Announces Positive Phase 1b Efficacy Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mi...

BRIDGEWATER, N.J., April 07, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated ...

VYNE Therapeutics Shares Jump On Encouraging Preclinical Data From VYN201 Program In Rheumatoid Arthritis

VYNE Therapeutics Inc (NASDAQ: VYNE) announced positive preclinical data from its VYN201 program in the rheumatoid arthritis (RA) animal model. The Company will start a first-in-human trial for VYN201 i...

VYNE Reports Positive Preclinical Data for Intra-Articular Injection of Pan-BET Inhibitor, VYN201, in an In Vivo Mode...

BRIDGEWATER, N.J., March 30, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company focused on developing proprietary, innovative, and diff...

VYNE Therapeutics Reports Year-End 2021 Financial Results and Provides Corporate Update

FMX114 demonstrated preliminary clinical safety and pharmacokinetics in Phase 1b study

VYNE Therapeutics' BET Inhibitor Shows Encouraging Preclinical Action In Skin Disorder

VYNE Therapeutics Inc (NASDAQ: VYNE) has announced preclinical data in an ex vivo skin model of vitiligo, a chronic autoimmune depigmenting disorder of the skin. In the preclinical model, pan-bromodomai...

VYNE Reports Positive Preclinical Data for Lead BET Inhibitor, VYN201, in Human Skin Model of Vitiligo

BRIDGEWATER, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company focused on developing proprietary, innovative, and diff...

VYNE Therapeutics to Present at 42nd Annual Cowen Healthcare Conference

BRIDGEWATER, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated ...

VYNE Therapeutics Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Ato...

Systemic bioavailability of JAK inhibitor (tofacitinib) and S1P receptor modulator (fingolimod) in topical formulation substantially lower compared to oral equivalents

VYNE Therapeutics Offloads Its Topical Minocycline Assets To Journey Medical In $450M+ Deal

Journey Medical Corporation (NASDAQ: DERM) has acquired Molecule Stabilizing Technology (MST) franchise, including Amzeeq (minocycline) topical foam and Zilxi (minocycline) topical foam from VYNE Therap...

VYNE Therapeutics Divests Topical Minocycline Assets

Transaction includes cash payments of $25 million and potential milestones of up to $450 million

VYNE Therapeutics to Participate at the LifeSci Partners 11th Annual Corporate Access Event

BRIDGEWATER, N.J., Jan. 03, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that management will participate in one-on-one investor meetings at t...

Do Options Traders Know Something About VYNE Therapeutics (VYNE) Stock We Don't?

Investors need to pay close attention to for VYNE Therapeutics (VYNE) stock based on the movements in the options market lately.